Preclinical Evaluation of a Nanobody-based SPECT Radiotracer 99mTc-AFN with Clinical Potential for Noninvasive Monitoring of Fibroblast Activation after Myocardial Infarction

The newly developed nanobody-based SPECT radiotracer, technetium 99m–labeled nanobody ( 99m Tc-AFN), noninvasively monitored fibroblast activation after myocardial infarction in preclinical models, supporting its potential use in clinical imaging.